Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Poziotinib in Recurrent/Metastatic Esophageal Squamous Cell Carcinoma
NCT03770988Phase 2Unknown
- Sponsor
- Yonsei University
- Start
- Apr 2019
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of poziotinib in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Yonsei University. Status: unknown.
02
Drugs
poziotinib
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT03770988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03770988.